Man Group PLC Vertex Pharmaceuticals Inc Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Man Group PLC holds 51,718 shares of VRTX stock, worth $24 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

51,718

Previous 197,296 73.79%

Holding current value

$24 Million

Previous $92.5 Million 73.99%

% of portfolio

0.07%

Previous 0.25%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $67 Million - $73.6 Million	-145,578 Reduced 73.79%	51,718 $24.1 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $130 Million - $161 Million	-330,628 Reduced 62.63%	197,296 $92.5 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $70.6 Million - $77.2 Million	173,126 Added 48.8%	527,924 $221 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $28.1 Million - $33.7 Million	81,952 Added 30.04%	354,798 $144 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $37.2 Million - $39.9 Million	-109,974 Reduced 28.73%	272,846 $94.9 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $9.29 Million - $10.4 Million	29,555 Added 8.37%	382,820 $135 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $63.2 Million - $72.1 Million	-223,133 Reduced 38.71%	353,265 $111 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $97.4 Million - $110 Million	340,716 Added 144.57%	576,398 $166 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $30.9 Million - $34.5 Million	112,869 Added 91.9%	235,682 $68.2 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $72.4 Million - $90.1 Million	-307,947 Reduced 71.49%	122,813 $34.6 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $118 Million - $139 Million	-532,765 Reduced 55.29%	430,760 $112 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $43.9 Million - $55.4 Million	-247,918 Reduced 20.46%	963,525 $212 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $67.4 Million - $75.4 Million	371,319 Added 44.2%	1,211,443 $220 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $38 Million - $44.8 Million	202,762 Added 31.81%	840,124 $169 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $60.1 Million - $70.1 Million	-290,549 Reduced 31.31%	637,362 $137 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $45.1 Million - $60.1 Million	217,679 Added 30.65%	927,911 $219 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $30.1 Million - $35.7 Million	117,797 Added 19.88%	710,232 $193 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $17 Million - $22.4 Million	-75,565 Reduced 11.31%	592,435 $172 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $86.2 Million - $107 Million	431,635 Added 182.61%	668,000 $159 Million
Q4 2019 Feb 18, 2020	BUY	$166.71 - $223.91 $28.6 Million - $38.5 Million	171,786 Added 266.01%	236,365 $51.8 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $11.3 Million - $12.7 Million	-67,846 Reduced 51.23%	64,579 $10.9 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $4.19 Million - $4.85 Million	25,460 Added 23.8%	132,425 $24.3 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $20.3 Million - $24.1 Million	-123,977 Reduced 53.68%	106,965 $19.7 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $20.6 Million - $26 Million	135,385 Added 141.68%	230,942 $38.3 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $6.83 Million - $7.85 Million	-40,728 Reduced 29.88%	95,557 $18.4 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $3.45 Million - $4.02 Million	23,668 Added 21.02%	136,285 $23.2 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $17.1 Million - $19.9 Million	112,617 New	112,617 $18.4 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account